Aigen Investment Management LP Buys New Holdings in Sotera Health (NASDAQ:SHC)

Aigen Investment Management LP purchased a new position in Sotera Health (NASDAQ:SHCFree Report) during the 4th quarter, HoldingsChannel reports. The institutional investor purchased 14,397 shares of the company’s stock, valued at approximately $243,000.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Swiss National Bank grew its position in Sotera Health by 1.0% in the 3rd quarter. Swiss National Bank now owns 217,400 shares of the company’s stock worth $3,257,000 after purchasing an additional 2,100 shares in the last quarter. Victory Capital Management Inc. grew its holdings in shares of Sotera Health by 12.9% in the third quarter. Victory Capital Management Inc. now owns 18,572 shares of the company’s stock valued at $278,000 after acquiring an additional 2,117 shares in the last quarter. DekaBank Deutsche Girozentrale purchased a new stake in shares of Sotera Health during the third quarter valued at approximately $58,000. Pacer Advisors Inc. boosted its position in Sotera Health by 79.4% in the fourth quarter. Pacer Advisors Inc. now owns 14,864 shares of the company’s stock worth $250,000 after purchasing an additional 6,580 shares during the last quarter. Finally, Quest Partners LLC bought a new position in Sotera Health in the 4th quarter valued at $139,000. Institutional investors and hedge funds own 91.03% of the company’s stock.

Insider Transactions at Sotera Health

In related news, Director Pincus & Co. Warburg sold 16,594,363 shares of the stock in a transaction on Monday, March 4th. The stock was sold at an average price of $14.31, for a total value of $237,465,334.53. Following the transaction, the director now owns 88,822,952 shares of the company’s stock, valued at $1,271,056,443.12. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other Sotera Health news, Director Pincus & Co. Warburg sold 16,594,363 shares of the stock in a transaction that occurred on Monday, March 4th. The shares were sold at an average price of $14.31, for a total transaction of $237,465,334.53. Following the transaction, the director now directly owns 88,822,952 shares in the company, valued at $1,271,056,443.12. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Michael P. Rutz sold 83,109 shares of the company’s stock in a transaction on Monday, March 4th. The shares were sold at an average price of $14.31, for a total transaction of $1,189,289.79. Following the completion of the sale, the insider now directly owns 544,409 shares of the company’s stock, valued at approximately $7,790,492.79. The disclosure for this sale can be found here. Insiders own 55.12% of the company’s stock.

Sotera Health Stock Performance

NASDAQ SHC opened at $11.20 on Monday. The company’s 50 day simple moving average is $11.43 and its two-hundred day simple moving average is $13.83. The stock has a market capitalization of $3.17 billion, a PE ratio of 58.95 and a beta of 2.08. The company has a debt-to-equity ratio of 5.39, a current ratio of 3.20 and a quick ratio of 2.86. Sotera Health has a 1 year low of $10.71 and a 1 year high of $19.40.

Sotera Health (NASDAQ:SHCGet Free Report) last posted its earnings results on Thursday, May 2nd. The company reported $0.11 EPS for the quarter, missing the consensus estimate of $0.12 by ($0.01). The business had revenue of $248.18 million for the quarter, compared to analysts’ expectations of $254.73 million. Sotera Health had a return on equity of 48.47% and a net margin of 5.09%. Analysts predict that Sotera Health will post 0.63 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have recently commented on the company. Piper Sandler initiated coverage on Sotera Health in a research note on Tuesday, May 21st. They set a “neutral” rating and a $13.00 target price on the stock. Barclays cut their price objective on shares of Sotera Health from $19.00 to $14.00 and set an “overweight” rating for the company in a report on Wednesday, April 10th. KeyCorp initiated coverage on shares of Sotera Health in a report on Tuesday, February 6th. They set a “sector weight” rating on the stock. Citigroup upgraded Sotera Health from a “neutral” rating to a “buy” rating and dropped their target price for the stock from $18.00 to $16.00 in a research report on Wednesday, April 3rd. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $20.00 price target on shares of Sotera Health in a research report on Monday, March 4th. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $16.92.

Read Our Latest Report on Sotera Health

Sotera Health Profile

(Free Report)

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.

Read More

Want to see what other hedge funds are holding SHC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sotera Health (NASDAQ:SHCFree Report).

Institutional Ownership by Quarter for Sotera Health (NASDAQ:SHC)

Receive News & Ratings for Sotera Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sotera Health and related companies with MarketBeat.com's FREE daily email newsletter.